Business Context and Reporting Period
This Form 8-K filing by Dare Bioscience, Inc. (Dare) reports corporate governance changes effective April 9, 2018. The company is a Delaware corporation headquartered in La Jolla, California, and is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on the election of a new director and related committee appointments.
Material Changes
- Board Expansion: The Board of Directors increased its size from five to six members.
- New Director Election: Jessica Grossman, M.D., was elected as a Class I independent director. Her term expires at the 2018 annual meeting of stockholders (expected in July 2018).
- Committee Changes: Dr. Grossman was appointed to the Nominating and Corporate Governance (N&CG) Committee. Roger Hawley resigned from the N&CG Committee.
- Committee Composition: The N&CG Committee now consists of Susan L. Kelley, M.D. (Chairperson) and Dr. Grossman.
Guidance, Outlook, and Management Commentary
The filing includes no financial guidance, outlook, or management commentary regarding business operations or risks. It notes that Dr. Grossman will not receive equity compensation immediately upon election but will receive it on the date of the 2018 annual meeting in accordance with the company's non-employee director compensation policy. An indemnification agreement will also be executed with Dr. Grossman.
Investor Verification Checklist
- Verify Dr. Grossman's independence status under Nasdaq Listing Rules Rule 5605(a)(2).
- Confirm the date of the 2018 annual meeting of stockholders to determine the timing of Dr. Grossman's equity compensation.
- Review the attached press release (Exhibit 99.1) for additional context on the board's strategic rationale.
- Check subsequent filings for the formal adoption of the indemnification agreement.